7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

Potentia Pharmaceuticals Appoint Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board

November 11, 2008

Louisville, Ky. –  Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today the appointments of Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to its Scientific Advisory Board effective November 6, 2008.

 

Dr. Seddon is a world known macular degeneration specialist and pioneer in nutritional and genetic research in age-related macular degeneration, as well as an international leader in the field of ophthalmic epidemiology. For more than 20 years Dr. Seddon has directed NIH-based research on epidemiologic, biologic, and genetic biomarkers for macular degeneration and has made original contributions in these areas. Dr. Seddon is Professor of Ophthalmology at Tufts University School of Medicine and founding director of the Ophthalmic Epidemiology and Genetics Service at the New England Eye Center. She was a vice-president and trustee of ARVO, and the recipient of the inaugural Maurice F. Rabb, Jr. Award from Prevent Blindness America, for dedication and contributions to prevention and treatment of age-related macular degeneration.

 

Dr. Sunness is an accomplished researcher in understanding how diseases cause loss of vision and has directed several National Institutes of Health-funded studies in this field. Currently, Dr. Sunness is a medical director at Hoover Services for Low Vision and Blindness at the Greater Baltimore Medical Center. Her clinical practice focuses on low vision and on retinal and macular disease. An ophthalmologist by training, Dr. Sunness is a leading world expert on geographic atrophy, the advanced dry form of age-related macular degeneration and has also pioneered new methods of measuring visual function. Dr. Sunness is also a leading world expert on how pregnancy affects the mother’s eyes, both in cases of pre-existing conditions like diabetes as well as when diseases develop during pregnancy.

 

"We are very fortunate to have individuals of Dr. Seddon's and Dr. Sunness' standing and knowledge join Potentia's Scientific Advisory Board," said Cedric Francois, M.D., Ph.D., President and Chief Executive Officer for Potentia. "They are both extremely accomplished and held in very high regard in their fields. Their valuable insights and expertise will be of great value as we continue to develop our drug candidate, POT-4, which we believe holds great promise as a leading drug candidate in the treatment of both dry and wet AMD."

 

 

Tags:

Please reload

NEWS